5'-Deoxyadenosine

5'-Deoxyadenosine

SCHEMBL4397160

C[C@H]1O[C@@H](n2cnc3c(N)ncnc32)C(O)C1O

nearest known ligand 0.69

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AHCY P23526 11/20 0.69
ADORA3 P0DMS8 3/20 0.69
ADORA2A P29274 2/20 0.69
ADORA2B P29275 2/20 0.69
DPP4 P27487 1/20 0.69
MEN1 O00255 1/20 0.69
SLC28A1 O00337 1/20 0.69
MAP3K7 O43318 1/20 0.69
SLC28A2 O43868 1/20 0.69
GAPDH P04406 1/20 0.69
MAPK1 P28482 1/20 0.69
ADORA1 P30542 1/20 0.69
STAT6 P42226 1/20 0.69
PI4KA P42356 1/20 0.69
KMT2A Q03164 1/20 0.69
SMN1; SMN2 Q16637 1/20 0.69
PI4K2B Q8TCG2 1/20 0.69
DOT1L Q8TEK3 1/20 0.69
SLC29A1 Q99808 1/20 0.69
PI4K2A Q9BTU6 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
5'-Deoxyadenosine SCHEMBL542617 1.00 AHCY (0.69) AHCYADORA3ADORA2AADORA2BDPP4
5'-Deoxyadenosine SCHEMBL3459556 1.00 AHCY (0.69) AHCYADORA3ADORA2AADORA2BDPP4
5'-Deoxyadenosine SCHEMBL14158945 1.00 AHCY (0.69) AHCYADORA3ADORA2AADORA2BDPP4
5'-Deoxyadenosine SCHEMBL3459552 1.00 AHCY (0.69) AHCYADORA3ADORA2AADORA2BDPP4
5'-Deoxyadenosine SCHEMBL15926823 1.00 AHCY (0.69) AHCYADORA3ADORA2AADORA2BDPP4
5'-Deoxyadenosine SCHEMBL17677150 1.00 AHCY (0.69) AHCYADORA3ADORA2AADORA2BDPP4
5'-Deoxyadenosine SCHEMBL12453581 1.00 AHCY (0.69) AHCYADORA3ADORA2AADORA2BDPP4
5'-Deoxyadenosine SCHEMBL14304623 1.00 AHCY (0.69) AHCYADORA3ADORA2AADORA2BDPP4
SCHEMBL4850058 0.99 AHCY (0.67) AHCYADORA3ADORA2AADORA2BDPP4
SCHEMBL6674526 0.99 AHCY (0.67) AHCYADORA3ADORA2AADORA2BDPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0787138-A4 RADIOACTIVE PHOSPHOROUS LABELING OF PROTEINS FOR TARGETED RADIOTHERAPY IMMUNOMEDICS INC (US) 2000-03-08 EP claimed
US-5976492-A Radioactive phosphorus labeled proteins for targeted radiotherapy IMMUNOMEDICS, INC. (US) 1999-11-02 US claimed
US-5728369-A Radioactive phosphorus labeling of proteins for targeted radiotherapy IMMUNOMEDICS, INC. (US) 1998-03-17 US claimed
EP-0787138-A1 RADIOACTIVE PHOSPHOROUS LABELING OF PROTEINS FOR TARGETED RADIOTHERAPY Immunomedics, Inc. (US) 1997-08-06 EP claimed
WO-1996011208-A1 RADIOACTIVE PHOSPHOROUS LABELING OF PROTEINS FOR TARGETED RADIOTHERAPY IMMUNOMEDICS, INC. (US) 1996-04-18 WO claimed
EP-4722358-A1 GLYCEROL DEHYDRATASE VARIANT AND USE THEREOF AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) 2026-04-08 EP disclosed
US-12522800-B2 Bacterial cultures for increasing vitamin B12 in plants HINOMAN LTD. (IL) 2026-01-13 US disclosed
EP-4611779-A1 A PREDICTIVE SCORE OF CANCER IMMUNOTHERAPY OUTCOME BASED ON ECOLOGICAL ANALYSIS OF GUT MICROBIOTA Institut Gustave-Roussy (FR) 2025-09-10 EP disclosed
US-12331343-B2 FAMIN assay methods CAMBRIDGE ENTERPRISE LIMITED (GB) 2025-06-17 US disclosed
WO-2024248535-A1 GLYCEROL DEHYDRATASE VARIANT AND USE THEREOF 아주대학교산학협력단 2024-12-05 WO disclosed
US-20240166675-A1 NOVEL PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY 2024-05-23 US disclosed
WO-2024094817-A1 A PREDICTIVE SCORE OF CANCER IMMUNOTHERAPY OUTCOME BASED ON ECOLOGICAL ANALYSIS OF GUT MICROBIOTA INSTITUT GUSTAVE ROUSSY (FR) 2024-05-10 WO disclosed
EP-0946732-A2 Method for the recombinant production of 1,3-propanediol GENENCOR INTERNATIONAL, INC. (US) 1999-10-06 EP disclosed
EP-0942989-A1 METHOD FOR THE PRODUCTION OF 1,3-PROPANEDIOL BY RECOMBINANT ORGANISMS E.I. DU PONT DE NEMOURS AND COMPANY (US) 1999-09-22 EP disclosed
WO-1998021339-A1 METHOD FOR THE PRODUCTION OF 1,3-PROPANEDIOL BY RECOMBINANT ORGANISMS E.I. DU PONT DE NEMOURS AND COMPANY (US) 1998-05-22 WO disclosed
WO-1998021341-A2 METHOD FOR THE RECOMBINANT PRODUCTION OF 1,3-PROPANEDIOL GENENCOR INTERNATIONAL, INC. (US) 1998-05-22 WO disclosed
US-5728369-A Radioactive phosphorus labeling of proteins for targeted radiotherapy IMMUNOMEDICS, INC. (US) 1998-03-17 US disclosed
EP-0037310-B1 SUBSTITUTED DEOXYADENOSINE DERIVATIVES MERRELL TORAUDE ET COMPAGNIE (FR) 1984-05-09 EP disclosed
US-4374128-A TREATING RAPID CELL PROLIFERATION MERRELL TORAUDE ET COMPAGNIE (FR) 1983-02-15 US disclosed
EP-0037310-A1 Substituted deoxyadenosine derivatives MERRELL TORAUDE ET COMPAGNIE (FR) 1981-10-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240166675-A1 NOVEL PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS PPIP5K2, NUDT1, NT5C3B AHCY 247/4885ADORA3 652/4885ADORA2A 941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.